29 December 2009

FDA Warning; WE ARE EXEMPT from Freedom of Info Act

FDA Approves Saphris Tablets (asenapine) To Treat Schizophrenia And Bipolar Disorder

when I went to look at the FDA at some of their memos to check on the tests, this is what I found:

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).

FDA Briefing Material

The company who did the research?  well, here is thier mission statement


To earn trust, every day.

At Schering-Plough, we aspire to earn the trust of doctors, patients and customers by providing a steady flow of innovative, science-based medicines and services that improve the health and well-being of people around the world.

To achieve these goals and grow our company, we are working to earn the trust of all stakeholders. We understand that earning trust demands hard work, sharp execution, integrity and transparency.

Our customers and patients are our most important constituents. Our vision for the new Schering-Plough clearly sets forth what we will do as a global team, what makes us special as a company and what will give us a competitive advantage.

No comments:

Post a Comment

Please feel free to post a comment!

These are the thoughts and feelings as they happen. The subject matter and verbage may be of a more mature nature, and may be considered sensitive by some. In respect for that, I shall try to remember to give headers (with some space before post) and attempt to just "suggest" sensitive verbage.

Peace, Blessings, I hope this can help some.